CurrentCardio
Get Weekly

Cardiometabolic & kidneyCohort study

SGLT2 Inhibitors and Mortality in Endometriosis With Type 2 Diabetes

JACC AdvPublished

  • retrospective cohort study
  • 1:1 propensity score matching
  • routinely collected health data
Read the original article ↗

Authors' conclusion

In a propensity-matched analysis of patients with endometriosis and T2D, use of SGLT2i on top of background metformin therapy was associated with lower mortality compared with metformin-based therapy without SGLT2i, with no significant differences in most cardiovascular outcomes.

Study context

Population
Adults with endometriosis and type 2 diabetes (T2D)matched cohort, 3,072 patients in each group
Participants
6,144 adults
Exposure
SGLT2i vs metformin-based therapy without SGLT2i
  • SGLT2in = 3,072
  • metformin-based therapy without SGLT2in = 3,072reference

Main finding

All-cause mortality · mean follow-up 2.8 ±1.8 years (median, 2.8; IQR: 3.7)

Hazard ratio

0.52

95% CI 0.38–0.72

P < 0.0001

Events by group

SGLT2i

0.65% per year

55 of 3,072

metformin-based therapy without SGLT2i

1.15% per year

115 of 3,072

SGLT2i vs metformin-based therapy without SGLT2i
HR 0.52 (95% CI 0.38–0.72); P < 0.0001

As reported in the abstract

Observational data: associations, not effects.

Further findings

Ischemic stroke/thromboembolism, acute myocardial infarction, atrial fibrillation, ventricular arrhythmia/cardiac arrest, heart failure, acute pulmonary edema/cardiogenic shock, peripheral artery disease

not significantly different

Safety

OutcomeHR (95% CI)P value
Progression to chronic kidney disease stage 4 to 5 · numerically higher with SGLT2i1.28 (0.99–1.64)P = 0.05

Original publication

SGLT2 Inhibitors and Mortality in Endometriosis With Type 2 Diabetes. JACC Adv. Published 1 April 2026. doi:10.1016/j.jacadv.2026.102681
Read the original article ↗PubMedCite RIS · BibTeX

Summarised from the published abstract; every number is checked against it